Understanding FAM27E4: A Potential Drug Target Or Biomarker (G107987001)

Target Name: FAM27E4

NCBI ID: G107987001

FAM27E4

Other Name(s): family with sequence similarity 27 member E4 | Family with sequence similarity 27, member E4 | FAM27E4P

Understanding FAM27E4: A Potential Drug Target Or Biomarker

The FAM27E4 protein is a member of the FAM27 family, which is characterized by a unique N-terminal region that contains a nucleotide-rich sequence similarity of 27 amino acids (1-27) between its N-terminus and the corresponding region of other family members. The sequence of FAM27E4 is highly conserved across species, and it has been identified as a potential drug target or biomarker.

The FAM27 family is characterized by a conserved core structure that consists of a unique N-terminal region that is rich in nucleotides and a C-terminal region that contains a characteristic Rossmann-fold (尾-sheet) that is responsible for the protein's stability and interactions with other molecules. The N-terminus of FAM27E4 is similar to that of other family members in that it contains a conserved nucleotide-rich region that is involved in the formation of a nucleotide-rich structure that can interact with other molecules.

One of the unique features of FAM27E4 is its sequence similarity with other proteins that are not members of the FAM27 family. This conservation of sequence across different species suggests that FAM27E4 may be a promising drug target or biomarker, as it may be able to interact with other molecules that are also targeted by drugs or used as biomarkers.

In addition to its potential as a drug target or biomarker, FAM27E4 is also a promising research tool for the study of protein structure and function. The conserved core structure of FAM27E4 makes it a useful template for studies of protein structure and function, as well as the development of new techniques for protein purification and analysis.

FAM27E4 has been identified as a potential drug target or biomarker through a variety of studies. For example, researchers have shown that FAM27E4 can interact with small molecules, such as inhibitors of the protein's activity, and that this interaction can be inhibited by small molecules that are known to be effective drug candidates. Additionally, studies have shown that FAM27E4 can interact with proteins that are involved in cellular signaling pathways, including the TGF-β pathway.

FAM27E4 may also be a potential drug target or biomarker based on its expression patterns in certain diseases. For example, studies have shown that FAM27E4 is expressed in a variety of tissues and that it is highly expressed in tissues that are affected by diseases that are characterized by inflammation, such as cancer and autoimmune diseases. Additionally, FAM27E4 has been shown to be involved in the regulation of cellular processes that are important in the development and progression of these diseases, such as the regulation of T cell function and the regulation of inflammation.

In conclusion, the FAM27E4 protein is a member of the FAM27 family that is characterized by a unique N-terminal region that contains a nucleotide-rich sequence similarity of 27 amino acids. The sequence of FAM27E4 is highly conserved across species and has been identified as a potential drug target or biomarker. Further studies are needed to fully understand the potential of FAM27E4 as a drug target or biomarker, as well as its role in the regulation of cellular processes that are important in the development and progression of diseases.

Protein Name: Family With Sequence Similarity 27 Member E4

The "FAM27E4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM27E4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets